Samsung Biologics
- All
- News
-
Samsung Pharmaceutical Arm Fined For $4 Billion Accounts Breach
The pharmaceutical arm of giant South Korean conglomerate Samsung was fined Wednesday for alleged accounting breaches amounting to nearly $4 billion, and had dealings in its shares suspended indefinitely.
-
Samsung BioLogics May Raise $2 Billion In IPO
The Samsung Group, under new de facto leader Jay Y Lee, has been keen to strengthen its biopharmaceutical businesses as the smartphones-to-construction business empire hunts for new sources of growth.
-
Samsung Unit to Invest $736 Million in Manufacturing Plant
Samsung Biologics, an unlisted arm of South Korea's Samsung Group, said on Friday it would invest 850 billion won ($736 million) to build a manufacturing facility, as the conglomerate steps up its expansion in the biopharmaceutical sector.
-
Samsung Pharmaceutical Arm Fined For $4 Billion Accounts Breach
The pharmaceutical arm of giant South Korean conglomerate Samsung was fined Wednesday for alleged accounting breaches amounting to nearly $4 billion, and had dealings in its shares suspended indefinitely.
-
Samsung BioLogics May Raise $2 Billion In IPO
The Samsung Group, under new de facto leader Jay Y Lee, has been keen to strengthen its biopharmaceutical businesses as the smartphones-to-construction business empire hunts for new sources of growth.
-
Samsung Unit to Invest $736 Million in Manufacturing Plant
Samsung Biologics, an unlisted arm of South Korea's Samsung Group, said on Friday it would invest 850 billion won ($736 million) to build a manufacturing facility, as the conglomerate steps up its expansion in the biopharmaceutical sector.
